헤르페스 감염 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Herpes Infection Treatment Market size is expected to reach USD 8.61 Billion in 2034 from USD 4.77 Billion (2025) growing at a CAGR of 6.77% during 2026-2034.

The Global Herpes Infection Treatment Market is growing due to the increasing prevalence of herpes simplex virus (HSV) infections worldwide. Rising awareness about sexually transmitted infections and better diagnostic methods are encouraging more patients to seek treatment. Governments and health organizations are also promoting awareness programs, which support early detection and medical intervention.

Antiviral medications remain the primary treatment option, and continuous research is improving their effectiveness. The expansion of healthcare services in developing countries is increasing patient access to treatment. In addition, the availability of online pharmacies and telemedicine services is making consultation and medication access easier for patients dealing with herpes infections.

In the future, the market is expected to grow with advancements in vaccine research and innovative antiviral therapies. Pharmaceutical companies are investing in research and development to introduce more effective and long-lasting treatment options. As awareness continues to increase and healthcare infrastructure improves globally, the herpes infection treatment market is projected to expand steadily in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Antiviral Medications
• Topical Treatments
• Vaccines
• Supportive Therapies

By Administration Route

• Oral
• Topical
• Intravenous
• Intradermal

By Patient Demographics

• Adults
• Adolescents
• Pediatric

By Infection Type

• Genital Herpes
• Oral Herpes

By Treatment Settings

• Hospitals
• Outpatient Clinics
• Home Care

COMPANIES PROFILED

• AbbVie, Johnson Johnson, Roche, Mylan, BristolMyers Squibb, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, Sanofi, Novartis, AstraZeneca, Pfizer, Merck Co, Gilead Sciences, GlaxoSmithKline, Amgen
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HERPES INFECTION TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Antiviral Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Topical Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Supportive Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HERPES INFECTION TREATMENT MARKET: BY ADMINISTRATION ROUTE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Administration Route
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Intradermal Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HERPES INFECTION TREATMENT MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Demographics
• 6.2. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adolescents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HERPES INFECTION TREATMENT MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Infection Type
• 7.2. Genital Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Oral Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HERPES INFECTION TREATMENT MARKET: BY TREATMENT SETTINGS 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Treatment Settings
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Outpatient Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HERPES INFECTION TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Treatment Type
  • 9.2.2 By Administration Route
  • 9.2.3 By Patient Demographics
  • 9.2.4 By Infection Type
  • 9.2.5 By Treatment Settings
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Treatment Type
  • 9.3.2 By Administration Route
  • 9.3.3 By Patient Demographics
  • 9.3.4 By Infection Type
  • 9.3.5 By Treatment Settings
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Treatment Type
  • 9.4.2 By Administration Route
  • 9.4.3 By Patient Demographics
  • 9.4.4 By Infection Type
  • 9.4.5 By Treatment Settings
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Treatment Type
  • 9.5.2 By Administration Route
  • 9.5.3 By Patient Demographics
  • 9.5.4 By Infection Type
  • 9.5.5 By Treatment Settings
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Treatment Type
  • 9.6.2 By Administration Route
  • 9.6.3 By Patient Demographics
  • 9.6.4 By Infection Type
  • 9.6.5 By Treatment Settings
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL HERPES INFECTION TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AbbVie
  • 11.2.2 Johnson & Johnson
  • 11.2.3 Roche
  • 11.2.4 Mylan
  • 11.2.5 Bristol-Myers Squibb
  • 11.2.6 Hikma Pharmaceuticals
  • 11.2.7 Teva Pharmaceutical Industries
  • 11.2.8 Sanofi
  • 11.2.9 Novartis
  • 11.2.10 AstraZeneca
  • 11.2.11 Pfizer
  • 11.2.12 Merck & Co
  • 11.2.13 Gilead Sciences
  • 11.2.14 GlaxoSmithKline
  • 11.2.15 Amgen